Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom
J.F. Lester(Cancer Research UK), Vivek Pawar, T. Mansy(Nottingham University Hospitals NHS Trust), Sarah Khan(Nottingham University Hospitals NHS Trust), Andrew Conn(Bradford Teaching Hospitals NHS Foundation Trust), Vaneet Nayar, Peter Martin(Northwestern University), Samuel Chan(York Teaching Hospital NHS Foundation Trust), Carles Escriu(Clatterbridge Cancer Centre NHS Foundation Trust), John Conibear(Barts Health NHS Trust), Emma Hudson(University of Oxford), Xinke Zhang(Hunan University of Science and Technology), Adeline Durand(Merck KGaA, Darmstadt (Germany)), Xiaohui Zhuo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ceri Powell(Swansea Bay University Health Board), Lauren Nelless, Juliet Brock(University Hospitals Sussex NHS Foundation Trust), Amerah Amin(Merck KGaA, Darmstadt (Germany))
Cited by 30
Related Papers
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
MAIT cells are activated during human viral infections
|Nature Communications|2016|526